Form 4: CVS Health Director Receives Deferred Stock Units

CVS Health director Alecia A. DeCoudreaux acquired 1,447.5039 deferred stock units as part of the company's non-employee director compensation policy.

Summary

• Director Alecia A. DeCoudreaux was granted 1,447.5039 deferred stock units on May 14, 2026.
• The units were issued in lieu of a semi-annual cash retainer under the CVS Health 2017 Incentive Compensation Plan.
• The units are valued at $97.15 per share.
• Following this transaction, the director holds a total of 42,181.8314 shares of common stock equivalents.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial outlook.

Positives

• Demonstrates director alignment with shareholder interests through equity-based compensation.

Negatives

• None identified.

Risks

• None identified.

Future Outlook

The deferred stock units will be converted into common stock at a future date as elected by the reporting person.

Industry Context

StockSavvy.ai notes that director equity grants in lieu of cash retainers are a standard corporate governance practice among large-cap healthcare companies to ensure long-term alignment between board members and shareholders.

Comparison to Industry Standards

• The use of deferred stock units for director compensation is consistent with standard practices at peer companies like Walgreens Boots Alliance and UnitedHealth Group.

Corporate Governance

Stakeholder Impact

• Minimal impact on shareholders as this is a standard compensation adjustment.

Next Steps

• Conversion of deferred stock units into common stock at a future date determined by the director.

Key Dates

Keywords

CVS Health, Form 4, Director Compensation, Insider Transaction, Deferred Stock Units